Medicare GLP-1 Insurance Coverage

Direct Answer

Standard Medicare Part D has a longstanding rule excluding coverage of GLP-1 medications used solely for weight loss. However, Medicare does cover these medications for other approved indications: type 2 diabetes (Ozempic, Mounjaro), cardiovascular risk reduction (Wegovy, since the FDA added this indication in 2024), and obstructive sleep apnea (Zepbound). A genuinely new pathway, the Medicare GLP-1 Bridge Program, opens real, direct weight-loss coverage starting July 1, 2026.

The Medicare GLP-1 Bridge Program

Starting July 1, 2026 and running through December 31, 2027, eligible Part D plan members gain access to Foundayo, Wegovy (injection or tablet), or Zepbound (KwikPen) specifically for weight loss, at a real, capped $50 copayment per 30-day supply. To qualify, you must be actively enrolled in a standalone Part D plan or a Medicare Advantage plan with prescription coverage. Your provider submits a prior authorization request and prescription to a CMS central processor, which reviews documentation and, once approved, pays the claim directly.

A Real, Notable Administrative Detail

CMS selected Humana as the national central processor handling Bridge Program prior authorization, claims, and pharmacy payment, regardless of which specific plan or carrier you're actually enrolled with, a real, structural detail worth understanding.

What Comes After the Bridge

The Bridge Program is explicitly temporary, running through the end of 2027. It was originally meant to lead into a follow-on program, the BALANCE Model, with a Medicare Part D launch planned for January 2027. As of current reporting, that Part D launch has been indefinitely shelved, meaning what happens after the Bridge Program ends in December 2027 is genuinely unresolved right now, worth watching directly rather than assuming a successor program is confirmed.

CMS Administrator Dr. Mehmet Oz has stated the Bridge Program exists because cost has kept many Americans from these treatments, framing it explicitly as a stopgap measure while broader reform is worked out.

A Real Note on Program Reach

Real, current modeling suggests the Bridge Program's actual reach may fall well short of the estimated 20 million Medicare beneficiaries who could clinically qualify for weight-loss medication, worth knowing before assuming broad, automatic access. If you're approved, you'll receive a letter in the mail confirming your GLP-1 drug is covered under the Bridge Program, and your prior authorization stays valid, including refills and dose changes, through December 31, 2027, unless you switch to a different GLP-1 medication.

Bottom Line

If you're on Medicare and specifically seeking weight-loss coverage, the real, current path is the Bridge Program, live since July 1, 2026, not standard Part D, which still excludes weight-loss-only use. Diabetes, cardiovascular, and sleep apnea indications remain covered under standard Medicare rules regardless of the Bridge Program.

Coverage policies and program details change frequently. This information reflects publicly available data as of August 11, 2026.

References

• CMS.gov: Medicare GLP-1 Bridge, Information for Providers and Part D Plans
• CMS: Medicare GLP-1 Bridge Program Launch Announcement
• Medicare.gov: Weight Loss Drugs Coverage
• AJMC: Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?

Related Resources

• Why Was My Medicare GLP-1 Bridge Claim Denied?
• Does My Pharmacy Accept the Medicare GLP-1 Bridge Program?

Browse All Insurance Coverage

See the complete GLP-1 Insurance Coverage hub

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com